@article{article_343780, title={The use of TgAb as a marker in differentiated thyroid cancer after ablation theraphy}, journal={Ege Journal of Medicine}, volume={48}, pages={19–22}, year={2009}, author={A, Kgün and B, Yazıcı and Ö, Erdim and Ü, Yararbaş and H, Özkılıç}, keywords={Thyroglobulin, differentiated thyroid carcinoma, thyroglobulin autoantibody}, abstract={Introduction: Aim was to evaluate thyroglobulin antibodies (TgAbs) variations before and after ablation and correlate thyroglobulin (Tg) and TgAbs levels to the outcome of disease in differentiated thyroid carcinoma (DTC) Material and Methods: We focused on 27 patients (22 female, 5 male, age range 24-70 years, 25 papillary and 2 follicular carcinoma) who had high levels of TgAbs in the post-surgical period. The follow-up was ranging form 30 to 88 months (mean: 45±16 months). The amount of I-131 administered was 75-175 mCi (mean 104.63±20,84 mCi ) Results: Successful ablation was achieved in 25 of 27 (92.5 %) patients. When pre and post ablation values were compared TgAb and Tg levels regressed significantly (Tg 1.66±3.70 ng/ml 0.19±0.25 ng/ml p}, number={1}, publisher={Ege University}